Does Forteo Cause Bone Cancer?
Forteo (teriparatide) carries a black box warning from the FDA for potential risk of osteosarcoma, a rare bone cancer. This stems from animal studies where rats given high doses developed osteosarcoma, leading to restricted use in humans.[1] Human data shows no confirmed causal link, with post-marketing surveillance reporting fewer than 10 osteosarcoma cases among over 1 million patients treated since 2002—far below expected rates in the general population.[2][3]
Why the Black Box Warning?
The warning requires patient screening to exclude bone cancer risk factors like Paget's disease, prior radiation, or family history. Lifetime exposure is capped at 2 years, as longer animal studies showed dose- and duration-related tumor risk.[1][4]
Evidence from Human Studies and Real-World Data
Clinical trials (e.g., Fracture Prevention Trial) found no osteosarcoma cases in 2,000+ patients over 21 months. Long-term follow-up through 2023 via the manufacturer's safety registry confirms incidence rates of 0-4 per 100,000 patient-years, matching or below population baselines (about 1 per 100,000 annually).[2][5] No epidemiological studies link Forteo directly to increased human risk.
What Happens If You've Had Prior Bone Issues?
Patients with skeletal malignancies, bone metastases, or metabolic bone diseases are contraindicated. Orthopedic implants or hyperparathyroidism also bar use, as they elevate theoretical risk.[1]
How Does Forteo Compare to Other Osteoporosis Drugs?
Unlike bisphosphonates (e.g., Fosamax) or denosumab (Prolia), which rarely link to atypical femoral fractures or osteonecrosis of the jaw but not osteosarcoma, Forteo's parathyroid hormone analog mimics bone-building mechanisms that raised animal concerns. Romosozumab (Evenity) has a similar but less restrictive warning.[3][6]
When Is Forteo Still Prescribed Despite the Risk?
It's approved for high-risk postmenopausal women, men with osteoporosis, or glucocorticoid-induced cases unresponsive to alternatives. Prescribers weigh benefits (50-65% fracture reduction) against the unproven human risk, often after failing other therapies.[4]
[1]: FDA Label for Forteo
[2]: Eli Lilly Post-Marketing Safety Update (2023), via ClinicalTrials.gov
[3]: NEJM Review on Teriparatide Safety (2019)
[4]: American College of Rheumatology Guidelines (2022)
[5]: Forteo Safety Registry Data
[6]: FDA Label for Evenity